Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Shire and Acceleron Pharma announce rare disease joint venture
October 2010
SHARING OPTIONS:

DUBLIN, Ireland—Shire PLC and Acceleron Pharma of Cambridge, Mass., recently announced a joint venture to develop muscle therapeutics for rare diseases. The collaboration will initially focus on ACE-031, an Acceleron drug candidate that is currently in a Phase IIa trial for the treatment of patients with Duchenne Muscular Dystrophy (DMD). Under the terms of the agreement, Shire will make an upfront payment to Acceleron of $45 million. Acceleron is eligible to receive additional development, regulatory and sales milestone payments of up to $165 million for the successful commercialization of ACE-031 in DMD, up to an additional $288 million for successful commercialization of other indications and molecules, and royalties on product sales. Shire will also make a contribution to global development costs.


Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.